Mark Gergen is the Chief Executive Officer of Poseida Therapeutics, Inc., a biotech company focused on developing innovative treatments. He took charge on February 1, 2022, following a leadership transition in the company. Gergen earned an MBA from Harvard Business...

Mark Gergen is the Chief Executive Officer of Poseida Therapeutics, Inc., a biotech company focused on developing innovative treatments. He took charge on February 1, 2022, following a leadership transition in the company. Gergen earned an MBA from Harvard Business School, which adds credibility to his business acumen. His experience is rich, having been President and Chief Business Officer before stepping in as CEO. His strategic approach has propelled Poseida into noticeable achievements, particularly in its clinical developments and research initiatives. In the fiscal year 2023, Gergen earned nearly $962,000 in total compensation, with a significant portion coming from performance-based bonuses, indicating a strong alignment between his pay and the company's success. Under his leadership, Poseida’s stock saw varied trading activity, with insider trading values peaking significantly during early 2023, suggesting a confident outlook from Gergen on the company’s financial health. His leadership seems to be directed toward a culture of performance and efficiency, aiming to meet corporate goals and push the boundaries of biotechnology. Gergen’s continued focus on advancing the company reflects his commitment to both innovation and shareholder value.